Antiobesity drug therapy.

In Reply : I thank Dr. Modarressi for these comments and agree that the impact of many glucagon-like peptide 1 (GLP-1) receptor agonists on the lowering of blood pressure is modest but significant when com- pared with other glucose-lowering agents and thus have exerted cardioprotective benefits. A